Scientists Skip Cell Line Validation

Despite known problems with contamination and mislabeled cell lines, most researchers continue to operate without authenticating cells’ identity.

Written byKerry Grens
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

WIKIMEDIA, NATIONAL INSTITUTES OF HEALTH (NIH)Cell line misidentity is a pervasive problem in life sciences, with contaminants (HeLa, in many cases) often masquerading as other cell types. Despite years of drum-banging by government agencies, nonprofit organizations, academic institutions, and private companies on the importance of cell-line validation, a new survey finds less than half of researchers heed the advice.

“The failure to authenticate cell lines is still not an impediment to publication or to obtaining research funding,” Leonard Freedman, the lead author of the survey and the president of the Global Biological Standards Institute (GBSI), said in a statement sent to The Scientist. “A systematic approach by the entire biomedical research community that ensures routinely documented cell authentication is needed to resolve this global problem. In its absence, the accuracy of published research using cell lines is in question.”

Freedman and his colleagues surveyed several hundred life scientists on their cell line handling protocols. Slightly more than half (52 percent) of the respondents said they never validated their cell lines, citing cost, time, and concerns it would delay research. Perhaps not surprisingly, then, only ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

  • kerry grens

    Kerry served as The Scientist’s news director until 2021. Before joining The Scientist in 2013, she was a stringer for Reuters Health, the senior health and science reporter at WHYY in Philadelphia, and the health and science reporter at New Hampshire Public Radio. Kerry got her start in journalism as a AAAS Mass Media fellow at KUNC in Colorado. She has a master’s in biological sciences from Stanford University and a biology degree from Loyola University Chicago.

    View Full Profile
Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies